Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repaglinide and metformin in Chinese type 2 diabetes
NCT00491725Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repaglinide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin at 18 weeks. Started Sep 2005; status: completed.
02
Drugs
repaglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00491725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491725.